Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Optimizing Immune Checkpoint Inhibitor Payloads for Oncolytic Virus-Based Immunotherapy

Project description

Engineered viruses for improved cancer immunotherapy

In nearly 80 % of solid tumours current immunotherapies fail. Oncolytic viruses – engineered viruses that selectively infect and destroy cancer cells – offer a promising alternative for this unmet clinical need. The goal of the ERC-funded CHECKVIR project is to develop a next-generation oncolytic virus platform that combines direct tumour-cell killing with immune checkpoint inhibition within a single therapeutic agent. Building on findings from the ERC-funded ONCO-VAX project, researchers will validate this approach in preclinical models and identify a clinical development candidate. CHECKVIR has the potential to deliver an effective treatment option for the millions of cancer patients worldwide who do not benefit from existing immunotherapies.

Objective

Despite novel innovations in immune-oncology over the last decades, up to 80% of solid cancers remain unresponsive to currently available approaches, highlighting an urgent unmet clinical need. CHECKVIR aims to develop and validate a next-generation oncolytic virus-based immunotherapy approach to overcome treatment resistance in solid cancers. The technology leverages an optimized oncolytic virus platform that is engineered to elicit immune checkpoint inhibitory functions, thereby combining efficient tumor cell killing and a potent immunotherapy approach within a single drug. Building upon innovative viral vector engineering and immune-modulating strategies developed within the ERC Starting Grant action, ONCO-VAX, CHECKVIR will enable critical proof of concept activities, leading to identification of a clinical development candidate and a de-risked path towards commercialization in order to enable real-world impact. By combining ground-breaking translational research with a preclinical validation, CHECKVIR will deliver an innovative and readily translatable solution to address the ongoing challenges in immune oncology and provide hope for improved outcomes for cancer patients worldwide who urgently need effective solutions.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-POC

See all projects funded under this call

Host institution

KLINIKUM DER TECHNISCHEN UNIVERSITÄT MÜNCHEN (TUM KLINIKUM)
Net EU contribution
€ 150 000,00
Address
ISMANINGER STRASSE 22
81675 Muenchen
Germany
Region
Bayern Oberbayern München, Kreisfreie Stadt
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)